Inclusion Criteria:  Patients ≥ 18 years and ≤ 70 years of age, male or female Histologically/radiologically diagnosed advanced unresectable hepatocellular carcinoma Patients had received sorafenib as systemic therapy for advanced HCC with radiographic assessment of Stable Disease (SD) according to mRECIST criteria ECOG performance status of 0-2 Child-Pugh score ≤ 7 At least one measurable target lesion according to mRECIST and at least one lesion ≥ 10 mm; the lesions previously treated by radiotherapy or local regional therapy must have imaging evidence of disease progression to be considered as target lesions Life expectancy ≥ 3 months A) White blood cell count ≥ 3.0 × 10 ^ 9/L, absolute neutrophil count ≥ 3.0 × 10 ^ 9/L, platelet count ≥ 50 × 10 ^ 9/L, hemoglobin > 100 g/L; B) INR ≤ 1.5 times the upper limit of normal, APTT ≤ 1.5 times the upper limit of normal or PTT ≤ 1.5 times the upper limit of normal; C) Total bilirubin ≤ 2.5 times the upper limit of normal; ALT and AST ≤ 5 times the upper limit of normal; serum creatinine ≤ 1.5 times the upper limit of normal Voluntarily participate in this study and sign the informed consent Female patients of childbearing age or male patients with sexual partners of childbearing age should take effective contraceptive measures throughout the treatment period and 6 months after treatment  Exclusion Criteria:  Pregnant or lactating women Diffuse liver cancer or tumor not amenable to mRECIST criteria Prior treatment with oncolytic virus (e.g., T-VEC) Patients who are known to be allergic to the study drug or its active ingredients Sorafenib administration < 14 days History of immunodeficiency or autoimmune disease, or chronic systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to enrollment Patients with any other unstable systemic disease or other malignancy that may reduce life expectancy Patients participate in another interventional clinical trial within 30 days